...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Not adding up!

If you think this is a good agreement for shareholders, then I'm glad if you're happy! Go celebrate it!

We have seen fantastic research by our scientists in both companies over the many years that we've been here, but it hasn't translated into real wealth creation here! In fact, the financings keep getting done at lower and lower prices. If that makes sense to you - considering "we're the world leaders in this field" and we just witnessed what Constellation went for and how we've advanced the development of Zen-3694 significantly - well then, why pop your balloon?

Share
New Message
Please login to post a reply